vs
Side-by-side financial comparison of Ellington Financial Inc. (EFC) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $78.2M, roughly 1.1× Ellington Financial Inc.). Ellington Financial Inc. runs the higher net margin — 28.9% vs 22.8%, a 6.1% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 8.7%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 1.8%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
EFC vs FDMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $78.2M | $85.1M |
| Net Profit | $22.6M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | 7.4% | 17.3% |
| Net Margin | 28.9% | 22.8% |
| Revenue YoY | 8.7% | 8508900.0% |
| Net Profit YoY | -26.2% | 139.1% |
| EPS (diluted) | $0.10 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $78.2M | $85.1M | ||
| Q3 25 | $82.8M | $90.0K | ||
| Q2 25 | $92.5M | $15.0K | ||
| Q1 25 | $82.9M | $14.0K | ||
| Q4 24 | $72.0M | $1.0K | ||
| Q3 24 | $67.0M | $3.0K | ||
| Q2 24 | $91.2M | $5.0K | ||
| Q1 24 | $75.5M | $28.0K |
| Q4 25 | $22.6M | $19.4M | ||
| Q3 25 | $29.5M | $-56.9M | ||
| Q2 25 | $42.9M | $-54.7M | ||
| Q1 25 | $31.6M | $-48.0M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $16.2M | $-43.8M | ||
| Q2 24 | $52.3M | $-35.0M | ||
| Q1 24 | $26.9M | $-32.4M |
| Q4 25 | 7.4% | 17.3% | ||
| Q3 25 | 31.1% | -67983.3% | ||
| Q2 25 | 38.3% | -396373.3% | ||
| Q1 25 | 37.3% | -383007.1% | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 24.0% | -1704400.0% | ||
| Q2 24 | 52.8% | -849120.0% | ||
| Q1 24 | 42.2% | -136200.0% |
| Q4 25 | 28.9% | 22.8% | ||
| Q3 25 | 35.7% | -63195.6% | ||
| Q2 25 | 46.4% | -364386.7% | ||
| Q1 25 | 38.2% | -342657.1% | ||
| Q4 24 | 42.6% | — | ||
| Q3 24 | 24.1% | -1461433.3% | ||
| Q2 24 | 57.4% | -699060.0% | ||
| Q1 24 | 35.6% | -115717.9% |
| Q4 25 | $0.10 | $0.43 | ||
| Q3 25 | $0.29 | $-1.01 | ||
| Q2 25 | $0.45 | $-0.98 | ||
| Q1 25 | $0.35 | $-0.86 | ||
| Q4 24 | $0.23 | — | ||
| Q3 24 | $0.19 | $-0.79 | ||
| Q2 24 | $0.62 | $-0.63 | ||
| Q1 24 | $0.32 | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $505.7M |
| Total Assets | $19.4B | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $201.9M | $402.7M | ||
| Q3 25 | $184.8M | $305.1M | ||
| Q2 25 | $211.0M | $293.2M | ||
| Q1 25 | $203.3M | $321.4M | ||
| Q4 24 | $192.4M | $424.9M | ||
| Q3 24 | $217.7M | $501.9M | ||
| Q2 24 | $198.5M | $541.9M | ||
| Q1 24 | $187.5M | $525.9M |
| Q4 25 | $1.8B | $505.7M | ||
| Q3 25 | $1.8B | $369.0M | ||
| Q2 25 | $1.7B | $420.9M | ||
| Q1 25 | $1.6B | $469.7M | ||
| Q4 24 | $1.6B | $510.6M | ||
| Q3 24 | $1.6B | $552.9M | ||
| Q2 24 | $1.6B | $588.3M | ||
| Q1 24 | $1.5B | $600.6M |
| Q4 25 | $19.4B | $566.7M | ||
| Q3 25 | $17.8B | $424.0M | ||
| Q2 25 | $17.1B | $473.6M | ||
| Q1 25 | $16.6B | $515.7M | ||
| Q4 24 | $16.3B | $560.4M | ||
| Q3 24 | $16.0B | $604.0M | ||
| Q2 24 | $15.1B | $620.1M | ||
| Q1 24 | $15.1B | $629.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-925.5M | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -40.92× | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-925.5M | $28.6M | ||
| Q3 25 | $-290.4M | $-46.5M | ||
| Q2 25 | $-210.5M | $-43.4M | ||
| Q1 25 | $-126.4M | $-47.8M | ||
| Q4 24 | $-430.5M | $-134.6M | ||
| Q3 24 | $-141.7M | $-29.4M | ||
| Q2 24 | $-88.6M | $-30.2M | ||
| Q1 24 | $-59.5M | $-29.1M |
| Q4 25 | — | $28.5M | ||
| Q3 25 | — | $-46.6M | ||
| Q2 25 | — | $-43.4M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | $-138.4M | ||
| Q3 24 | — | $-31.2M | ||
| Q2 24 | — | $-30.6M | ||
| Q1 24 | — | $-29.8M |
| Q4 25 | — | 33.5% | ||
| Q3 25 | — | -51765.6% | ||
| Q2 25 | — | -289620.0% | ||
| Q1 25 | — | -345635.7% | ||
| Q4 24 | — | -13837100.0% | ||
| Q3 24 | — | -1038966.7% | ||
| Q2 24 | — | -611840.0% | ||
| Q1 24 | — | -106421.4% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | — | 101.1% | ||
| Q2 25 | — | 440.0% | ||
| Q1 25 | — | 4507.1% | ||
| Q4 24 | 0.0% | 378600.0% | ||
| Q3 24 | 0.0% | 59266.7% | ||
| Q2 24 | 0.0% | 6980.0% | ||
| Q1 24 | 0.0% | 2535.7% |
| Q4 25 | -40.92× | 1.47× | ||
| Q3 25 | -9.84× | — | ||
| Q2 25 | -4.90× | — | ||
| Q1 25 | -3.99× | — | ||
| Q4 24 | -14.04× | — | ||
| Q3 24 | -8.76× | — | ||
| Q2 24 | -1.69× | — | ||
| Q1 24 | -2.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
